We study how disruption of the NAD⁺–PARP1–XRCC1 axis contributes to persistent DNA damage and metabolic stress in ALS. Therapeutic approaches include PARP inhibitors, NAD-boosting agents, and mRNA-LNP delivery to neurons and glia. Our aim is to protect against neuronal death and slow disease progression.